Baltimore 14.10.2012 – Research on Vacc-4x and Vacc-C5 is today presented at the Annual Meeting of Institute of Human Virology Baltimore 14 October: Bionor Pharma (OSE: BIONOR) presents today research of the Company’s two HIV vaccines Vacc-4x and Vacc-C5, and the combination of these two vaccines at the Annual International Meeting of Institute of Human …
Oslo 13.08.2012 – Study of Vacc-4x Combined with Celgene`s Revlimid® (lenalidomide) in HIV Patients with Impaired Immune System Approved to Begin News Summary Placebo-controlled, double-blind clinical study combining Vacc-4x with Celgene`s Revlimid® (lenalidomide) approved to start at four clinics in Germany Study seeks to improve the immunological response in patients who have failed to recover …
Oslo 20.07.2012 – Therapeutic HIV Vaccine Vacc-4x Improves Quality of Immune Responses in HIV Patients, Resulting in Long-Term Reduction in Viral Load and Potential for Periodic “Boosts” that Could Result in New Treatment Option for People Living with HIV/AIDS. Bionor researchers report findings at AIDS 2012 “Towards an HIV Cure” pre-conference symposium. News summary • Bionor …
